Cambridge Investment Research Advisors
PVCT

Cambridge Investment Research Advisors’s PROVECTUS BIOPHARMACEUTICALS, INC. (DE) PVCT Stock Holding History

Cambridge Investment Research Advisors’s Portfolio PVCT Stock Details PVCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-18,824
Closed -$2K – 1873
2016
Q3 		$2K Hold
18,824
– – ﹤0.01% 1741
2016
Q2 		$7K Buy
18,824
+2,560
+16% +$974 ﹤0.01% 1555
2016
Q1 		$6K Hold
16,264
– – ﹤0.01% 1603
2015
Q4 		$6K Hold
16,264
– – ﹤0.01% 1573
2015
Q3 		$9K Buy
+16,264
New +$8.33K ﹤0.01% 1426
2014
Q4 		– Sell
-12,664
Closed -$13K – 1534
2014
Q3 		$13K Buy
+12,664
New +$12.3K ﹤0.01% 1455

Other funds holding PVCT

CCB
Cutter & Co Brokerage Ballwin, Missouri $423M AUM 15.02% 1-Year Est. Return
HFBOT
Home Federal Bank of Tennessee Knoxville, Tennessee $463M AUM 24.62% 1-Year Est. Return

Cambridge Investment Research Advisors's PVCT Position: Q4 2016 in Review

Cambridge Investment Research Advisors sold out of PROVECTUS BIOPHARMACEUTICALS, INC. (DE) (PVCT) in Q4 2016, closing a stake of 18,824 shares — an estimated $2K sold.

Cambridge Investment Research Advisors first reported a position in PVCT in Q3 2014 and held it in 6 quarters. The position peaked at $13K in Q3 2014. 8 funds tracked by Wall St. Rank hold PVCT as of Q4 2016.

  • Cambridge Investment Research Advisors reported no remaining PROVECTUS BIOPHARMACEUTICALS, INC. (DE) position as of Q4 2016 after selling out during the quarter.
  • Cambridge Investment Research Advisors sold 18,824 PROVECTUS BIOPHARMACEUTICALS, INC. (DE) shares in Q4 2016, an estimated $2K.
  • Cambridge Investment Research Advisors first reported a position in PROVECTUS BIOPHARMACEUTICALS, INC. (DE) in Q3 2014 and held it in 6 quarters.
  • Cambridge Investment Research Advisors's PROVECTUS BIOPHARMACEUTICALS, INC. (DE) position peaked at $13K in Q3 2014.
  • 8 funds tracked by Wall St. Rank held PROVECTUS BIOPHARMACEUTICALS, INC. (DE) as of Q4 2016.

Based on Cambridge Investment Research Advisors's 13F filing for Q4 2016, filed 13 Feb 2017.